Building the future of cell therapies on a chip

Mekonos is advancing a proprietary cell-engineering platform that offers unprecedented precision in the delivery of multiplexed cargo into even the most fragile of cells.

The power of scalable silicon technology

Our platform is creating a future where personalized medicine is accessible to all

There is a better way, and Mekonos is rising to the challenge.

In 2022, the medical landscape witnessed the approval of six advanced therapies, including four gene therapies, one cell therapy, and one RNA therapy. Currently there are over 10 new cell and gene therapy products awaiting approval in the US and Europe. However, this vibrant arena faces limitations:

  • Inefficient delivery methods

  • Costly, risky development

  • Complex supply chains

Mekonos is stepping up to address these issues head-on.

 
Stem cell

Supporting better health, one cell at a time

Our unique chip architecture for cell engineering aligns single nanoneedles to individually trapped cells — “one needle, one cell” — ensuring that each cell receives the same amount of molecular cargo, resulting in a highly homogenous population of modified cells.